Does Dexmedetomidine Affect Opioid Consumption Following Orthognathic Surgery?

Area of Science:

• Anesthesiology
• Pharmacology
• Pain Management

Background:

• Controversy exists regarding dexmedetomidine's (DEX) effectiveness as an opioid-sparing agent.
• Limited data on DEX's impact on postoperative opioid consumption in orthognathic surgery.

Purpose of the Study:

• To quantify the association between intraoperative dexmedetomidine (DEX) and 24-hour postoperative opioid consumption.
• To evaluate DEX's effect on pain scores and patient-controlled analgesia (PCA) use in orthognathic surgery patients.

Main Methods:

• Single-blind randomized prospective cohort study.
• Patients undergoing orthognathic surgery were randomized to receive DEX or no DEX.
• Primary outcome: 24-hour postoperative opioid consumption (MME). Secondary outcomes: Visual Analog Scale (VAS) pain scores and PCA parameters.

Main Results:

• No statistically significant difference in 24-hour MME consumption between DEX and control groups (P=.9).
• No significant difference in pain scores at 6 hours (P=.1).
• Lower VASPCA scores observed in the DEX group (P<.01), but PCA attempt-to-bolus ratio was identical.

Conclusions:

• Dexmedetomidine administration was not associated with reduced opioid consumption following orthognathic surgery.
• While DEX may influence patient-reported pain scores, its opioid-sparing effect in this context remains unproven.
• Further research is needed to clarify DEX's role in multimodal analgesia for orthognathic procedures.